HomeLBank Stocks
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc

Greenwich Lifesciences Inc (GLSI)

24HHigh$19.2824HLow$15.73
$18.70
+0.16%

Last updated: 2026-11-17 10:28:52

K-Line Chart, actual market data is subject to the trading page.

Key Data

Prev. Open
$16.06
Prev. Close
$18.70
Prev. Day's Range
$15.73 - $19.28
52W Range
$7.78 - $34.10
Trading Volume
1.061M
MC
$219.292M
P/E Ratio
--
EPS
$-1.53

Company Overview

NASDAQ

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
HeadquartersBUILDING 14, STAFFORD, TX, UNITED STATES, 77477
CountryUSA
Listing Date2020-09-25
Fiscal Year Ended2026-06-30
Shares Outstanding14.678M
CIK Code1799788

Financial Metrics

Indicator2026-06-302026-03-312025-12-312025-09-30
Income$0$3.558K$0$0
Operating Expenses--$1.779K----
Net Income-$3.949M-$5.657M-$7.923M-$4.152M
Net Profit Margin---158997.7%----
Earnings Per Share--$-0.39$-0.55$-0.30
EBITDA-$3.947M-$5.657M-$7.945M-$4.152M
Effective Tax Rate--------

FAQ

Greenwich LifeSciences, Inc. (GLSI) specializes in developing immunotherapy treatments aimed at preventing the recurrence of breast cancer. Its lead product candidate, GP2, focuses on addressing unmet medical needs in HER2/neu-positive breast cancer patients. The company operates within the biotechnology sector and the cancer treatment industry.
The lead candidate, GP2, is designed to prevent the recurrence of breast cancer in patients who have completed surgery and HER2-targeted therapies. It uses a T-cell-based immunotherapy platform to provide prolonged therapeutic benefits. GLSI aims to target markets with significant unmet needs in oncology.
Greenwich LifeSciences operates in the biotechnology sector, focusing on oncology. Specifically, its efforts are directed at the cancer immunotherapy industry, where it seeks novel solutions for cancer recurrence prevention.
GLSI’s main competitors include other biotechnology firms developing immunotherapies targeting HER2-positive breast cancer and broader cancer treatments. Companies like Genentech (a Roche subsidiary) and other oncology-focused biotech firms may compete with GLSI in similar therapeutic areas.
Key risks include the potential of clinical trial failures, regulatory hurdles, and competition in the oncology market. The success of GLSI’s business mainly depends on the approval and commercialization of its lead product, GP2. Additionally, as a clinical-stage company, it may face financial constraints until revenue generation begins.
No, Greenwich LifeSciences does not currently pay a dividend. As a clinical-stage biotechnology company, GLSI prioritizes research and development over dividend distribution. Investors typically focus on future growth potential rather than income generation when considering this type of company.
If GP2 achieves regulatory approval and commercial success, GLSI could address a critical unmet need in preventing breast cancer recurrence, creating a strong position in the oncology market. This success could lead to partnerships, licensing revenues, or an expanded research pipeline.
As a clinical-stage company, GLSI primarily relies on external funding sources such as equity issuances, partnerships, or grants to finance its operations and drug development programs. Since it does not currently generate revenue, securing continuous funding is essential for its progress.
Risk Warning
  1. 1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
  2. 2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
  3. 3.The information contained on this page is for reference only and does not constitute any investment advice.